It will affect patients, as well as Novo Nordisk, if reimbursements for the insulin analogs and GLP-1 analogs will be altered, as the Danish Reimbursement Committee has suggested, according to Claus Dall Andersen, who is Head of Market Access in Novo Nordisk Denmark.
“We notice that various clauses have been set up for the groups to which Levemir and Victoza belong and we will study them now and take a good look at the underlying reasons for those clauses. But generally speaking we think it is a pity to impose limits on patients’ access to innovative medicine in this way,” he tells Medwatch.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app